Gritstone, BioXcel Expect to Report Catalysts in July 2020; 2Q SanaCurrents Update
Gritstone Oncology (NASDAQ:GRTS) plans to hold a conference call and webcast at 8 am Eastern on July 13, 2020, to [...]
While Zynerba Hits on ASD; SanaCurrents Suspending Coverage of CONNECT-FX
On Wednesday, May 27, Zynerba (NASDAQ:ZYNE) reported positive data from its phase II trial testing its cannabinoid drug Zygel to [...]
SanaCurrents Adds ASD Phase II Trial as a Catalyst for Zynerba (ZYNE)
Zynerba Catalyst Update Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) recently affirmed it plans to release results of two, phase II clinical trials [...]
-
Acceleron Hits Second Catalyst; Eight More SanaCurrents Catalysts Expected For 2Q 2020 GalleryAcceleron Hits Second Catalyst; Eight More SanaCurrents Catalysts Expected For 2Q 2020
Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates
Acceleron Hits Second Catalyst; Eight More SanaCurrents Catalysts Expected For 2Q 2020
Onconova Coverage suspended, Oragenics falls short in Phase II trial. The FDA last week approved Acceleron Pharma Inc. (NASDAQ:XLRN) luspatercept [...]
-
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X GalleryZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X
Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X
3Q ‘19 catalyst, CBD treatment for Fragile X SanaCurrents is providing a pivotal sentiment rating to the results of a [...]